TAVRA supplies off-the-shelf, bone marrow-derived mesenchymal stem cell biologics sourced from young, healthy donors aged 18-25 for use by licensed physicians in orthopedic, sports medicine, and pain-focused practices. Manufactured in an FDA-registered, cGMP-compliant, ISO 7-certified cleanroom, each lot is released with a third-party verified Certificate of Analysis covering viability, potency, purity, and sterility. The product is designed for immediate point-of-care use, with clinical studies demonstrating results in alleviating pain, increasing joint function, and speeding wound healing.
Funding
Funding not disclosed
Founders
Product
Problem
Regenerative medicine treatments using stem-cell biologics often suffer from variability in cell quality, inconsistent manufacturing standards, and limited availability, making it difficult for clinicians to offer reliable, predictable therapies. Many products lack rigorous quality controls or require complex preparation, delaying treatment and undermining patient confidence in regenerative approaches.
Solution
TAVRA provides a higher standard for stem-cell biologics by offering human bone marrow-derived mesenchymal stem cells (BM-MSCs) sourced from young, healthy donors aged 18-25, which have demonstrated significant results in clinical studies for alleviating pain, increasing joint function, and speeding wound healing. The product is manufactured in an FDA-registered, cGMP-compliant, ISO 7-certified cleanroom and is available off-the-shelf, ready for immediate use at the point of care. Each lot is released with a third-party verified Certificate of Analysis covering viability, potency, purity, and sterility, ensuring predictable cell potency and product safety. TAVRA's deliberate design emphasizes biological rationale, manufacturing rigor, and transparency, supporting licensed physicians in delivering localized regenerative therapies that meaningfully support tissue health, function, and recovery.
Target Audience
Primary customers are licensed physicians in orthopedic, sports medicine, and pain-focused clinical practices seeking reliable, high-quality stem-cell biologics for localized regenerative therapies.
Features
- Bone marrow-derived mesenchymal stem cells (BM-MSCs) from young, healthy donors aged 18-25 for enhanced potency
- Manufactured in an FDA-registered, cGMP-compliant, ISO 7-certified cleanroom to ensure high-quality production standards
- Off-the-shelf availability with immediate readiness for point-of-care clinical use, eliminating preparation delays
- Third-party verified Certificate of Analysis for each lot covering viability, potency, purity, and sterility
- Demonstrated clinical results in alleviating pain, increasing joint function, and speeding wound healing
- Conservative, transparent approach anchored in biological rationale and manufacturing rigor to reduce variability